Latest news with #PYCTherapeuticsLimited
Business Insider
04-05-2025
- Business
- Business Insider
Bloom Burton Remains a Buy on PYC Therapeutics Limited (PYC)
Bloom Burton analyst David Martin PhD maintained a Buy rating on PYC Therapeutics Limited (PYC – Research Report) on April 30 and set a price target of A$4.00. The company's shares closed last Friday at A$1.23. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Martin PhD covers the Healthcare sector, focusing on stocks such as Knight Therapeutics, Aurinia Pharmaceuticals, and AbCellera Biologics. According to TipRanks, Martin PhD has an average return of 14.4% and a 44.28% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for PYC Therapeutics Limited with a A$3.14 average price target, representing a 156.33% upside. In a report released on April 30, Bell Potter also maintained a Buy rating on the stock with a A$2.30 price target.
Business Insider
30-04-2025
- Business
- Business Insider
Bell Potter Sticks to Their Buy Rating for PYC Therapeutics Limited (PYC)
Bell Potter analyst Thomas Wakim maintained a Buy rating on PYC Therapeutics Limited (PYC – Research Report) today and set a price target of A$2.30. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. According to TipRanks, Wakim is an analyst with an average return of -13.4% and a 23.08% success rate. Wakim covers the Healthcare sector, focusing on stocks such as Opthea , Clinuvel Pharmaceuticals , and CSL. Currently, the analyst consensus on PYC Therapeutics Limited is a Strong Buy with an average price target of A$3.35.
